Found 706 clinical trials
UPCC 07117: A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination with Paclitaxel in Patients with Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry
Request for collaborative review: WIRB serving as IRB of record.
UPCC 11917: A Dose-Finding Phase 1 Study of TAS-120 in Patients With Advanced Solid Tumors With or Without Fibroblast Growth Factor/Receptor (FGF/FGFR)-Related Abnormalities followed by a Phase 2 Study in Patients with Advanced Solid Tumors with FGF/FGFR-Related Abnormalities
Request for collaborative review: WIRB serving as IRB of record.
A Multiple-Site Phase 1/2 Safety and Efficacy Trial of AGTC 402 a Recombinant Adeno-associated Virus Vector Expressing CNGA3 in Patients with Congenital Achromatopsia Caused by Mutations in the CNGA3 Gene
Achromatopsia is an inherited retinal disorder characterized by markedly reduced visual acuity, nystagmus, photoaversion (intolerance to bright light), a small central scotoma, eccentric viewing, and complete or severe loss of color discrimination. The genetic mutations of the disease can be established in the majority of individuals. Approximately 25% are caused …
Cancer detection rate of Abbreviated (Fast) Breast MRI (AB-MR) after negative Digitial Breast Tomosynthesis in Women status post Conservation Therapy (BCT)
Women treated for primary breast cancer who undergo breast conservation therapy face an increased risk of developing a second breast cancer in the ipsilateral and the contralateral breast. Although mammographic screening is recommended annually, the sensitivity of mammography is limited in these patients due to the post treatment changes from …
Randomized Controlled Trial to Evaluate the Effect of Lost Wage Reimbursement to Potential Kidney Donors on Living Donation Rates
This study is being done to learn if offering to reimburse kidney donors for wages they would lose by being off work during the donation evaluation and surgery process increases the likelihood of the kidney transplant recipient to receive a living kidney transplant within one year. Eligible subjects will be …
PHASE I TRIAL OF AUTOLOGOUS T CELLS ENGINEERED TO EXPRESS NY-ESO-1 TCR AND GENE EDITED TO ELIMINATE ENDOGENOUS TCR AND PD-1
This is a Phase 1 first-in-human trial proposed to determine the safety profile and manufacturing feasibility of a single infusion of NYCE T cells on adult patients with myeloma, synovial sarcoma, and myxoid/round cell liposarcoma, and melanoma who have relapsed or refractory tumors expressing NY-ESO-1 antigen.
ADP-0000-002: Long Term Follow-up of Subjects Exposed to NY-ESO-1c259 T A Genetically Engineered NY-ESO-1 Specific T Cell Receptor
This non-therapeutic, multi-center LTFU study involves up to 15 years post-infusion monitoring of subjects who have been exposed to lentivirus-mediated gene transfer in Adaptimmune clinical studies. Subjects will undergo clinical evaluation with careful attention to adverse events possibly related to gene transfer/lentivirus-induced diseases. Blood samples will be collected. Subjects will …
